{
    "clinical_study": {
        "@rank": "51957", 
        "arm_group": [
            {
                "arm_group_label": "Bortezomib Dexamethasone", 
                "arm_group_type": "Experimental", 
                "description": "Bortezomib (SC) and Dexamethasone (PO) every 2 weeks"
            }, 
            {
                "arm_group_label": "No prolonged therapy is scheduled", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "Bortezomib Dexamethasone (Biochemical relapse)", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, open label study designed to evaluate the efficacy and\n      safety of prolonged treatment with bortezomib twice monthly and dexamethasone after a\n      salvage treatment containing bortezomib for relapsed or refractory multiple myeloma\n      patients."
        }, 
        "brief_title": "Maintenance Therapy With Subcutaneous Bortezomib", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient is of a legally consenting age as defined by local regulations.\n\n          2. Patient is, in the investigator(s) opinion willing and able to comply with the\n             protocol requirements.\n\n          3. Patient has given voluntary written informed consent before performance of any\n             study-related procedure not part of normal medical care, with the understanding that\n             consent may be withdrawn by the patient at any time without prejudice to their future\n             medical care.\n\n          4. Female patient is either post-menopausal for 24 consecutive months or surgically\n             sterilised or agree to continuous abstinence from heterosexual sexual contact or\n             willing to use two acceptable method of birth control at the same time (one highly\n             effective method and one additional effective method) (Highly Effective Methods:\n             Intrauterine device -IUD-; Hormonal -birth control pills, injections, implants-;\n             tubal ligation; partner's vasectomy; Additional Effective Methods: Latex condom;\n             Diaphragm; Cervical Cap) for 4 weeks prior to beginning study drug therapy, during\n             study drug therapy (including dose interruption) and for 4 weeks after\n             discontinuation of therapy.\n\n          5. Male patient agrees to use an acceptable method for contraception (i.e., condom or\n             abstinence) during study drug therapy (including dose interruption) and for 4 weeks\n             after discontinuation of bortezomib therapy.\n\n          6. Patient was previously diagnosed with multiple myeloma based on standard criteria.\n\n          7. Patient is relapsed or refractory after one to three lines of treatment and the last\n             one must be a bortezomib-containing regimen, without evidence of progressive disease.\n\n          8. Patient had previously received at least 4 cycles of a salvage treatment containing\n             bortezomib, before enrolment, without evidence of progressive disease.\n\n          9. Patient must be enrolled and start therapy within 45 days from the completion of the\n             last salvage cycle containing Bortezomib.\n\n         10. Before the salvage treatment with bortezomib-based regimens, patient must have\n             measurable disease\n\n        Exclusion Criteria:\n\n          1. Any serious medical condition, laboratory abnormality or psychiatric illness that\n             prevented the subject from signing the informed consent form or placed the subjects\n             at unacceptable risk.\n\n          2. Pregnant or lactating females\n\n          3. Known positive for HIV or active infectious hepatitis type A, B or C\n\n          4. Peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by National\n             Cancer Institute Common Toxicity Criteria (NCI CTC) 4.0\n\n          5. Infiltrative pulmonary disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913730", 
            "org_study_id": "26866138-MMY-2084"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bortezomib Dexamethasone", 
                    "Bortezomib Dexamethasone (Biochemical relapse)"
                ], 
                "intervention_name": "Bortezomib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Bortezomib Dexamethasone", 
                    "Bortezomib Dexamethasone (Biochemical relapse)"
                ], 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bortezomib", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Myeloma", 
            "Refractory", 
            "Relapsed"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "contact": {
                "last_name": "Pellegrino Musto, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Rionero in Vulture", 
                    "country": "Italy", 
                    "state": "Potenza"
                }, 
                "name": "Irccs Crob"
            }, 
            "investigator": {
                "last_name": "Pellegrino Musto", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to Progression", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913730"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Survival Progression Free Survival", 
                "measure": "Survival", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Objective overall response rate (ORR)", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Duration of response", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Time to response", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Time to the next anti-myeloma therapy (TNT)", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "TTP measured from the beginning of the salvage treatment", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Role of the type of salvage treatment", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Role of previous treatments", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Incidence of grade 3 and 4 hematological and non-hematological adverse events (AEs)", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Exploratory assessment on prognosis (ISS, age and FISH abnormalities)", 
                "measure": "Response", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Stichting Hemato-Oncologie voor Volwassenen Nederland", 
        "sponsors": {
            "collaborator": {
                "agency": "Fondazione Neoplasie Sangue Onlus", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Stichting Hemato-Oncologie voor Volwassenen Nederland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}